Last reviewed · How we verify
NCT02910284
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
trial testing Observational in Genital Herpes Simplex Type 2 in 140 participants. Completed in 14 July 2017.
14 July 2017
Quick facts
| Lead sponsor | Genocea Biosciences, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 140 |
| Start date | 16 September 2016 |
| Primary completion | 14 July 2017 |
| Estimated completion | 14 July 2017 |
| Sites | 13 locations across United States |
Drugs / interventions tested
- Observational — full drug profile →
Conditions studied
- Genital Herpes Simplex Type 2 — all drugs for Genital Herpes Simplex Type 2 →
Sponsor
Genocea Biosciences, Inc. — full company profile →
Who can join
Adults 18 to 50, any sex, with Genital Herpes Simplex Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a follow-up study from Study GEN-003-002 to evaluate long-term efficacy and immunogenicity of GEN-003 in subjects with genital HSV-2 infection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02910284
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Observational
Trials testing the same drug.
- NCT07356700 — Deciphering the Factors of Longevity Through a Multi-Omics Study in Long-Lived Individuals in Hong Kong · not yet recruiting
- NCT07381751 — Artificial Intelligence-assisted MDS-UPDRS Assessment for Parkinson's Disease · not yet recruiting
- NCT07347574 — NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in HK · not yet recruiting
- NCT07338968 — A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma · not yet recruiting
- NCT06792994 — A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients Wi · not yet recruiting
Other Genocea Biosciences, Inc. trials
Trials by the same sponsor.
- NCT04596033 — TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy · Phase 1 · terminated
- NCT03633110 — Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine · Phase 1, PHASE2 · completed
- NCT03146403 — Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02910284 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Genocea Biosciences, Inc.
- Last refreshed: 20 October 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02910284.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing